医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Establishment of Nitto BioPharma, Inc.

2016年01月25日 PM11:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Japan’s leading diversified materials manufacturer Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007) established a new company, Nitto BioPharma, Inc., with a focus on pharmaceutical development. Nitto has been conducting their first anti-liver fibrosis drug program (ND-L02-s0201), which is now in clinical trials in the US, Europe and Japan, and has several other pipelines of intractable diseases in the discovery stage.

Along with the establishment of the new company, Nitto plans to set up a new facility mid-2016 in the center of the Life Sciences hub in San Diego, California.
Going forward, drug discovery and development ventures, such as an anti-fibrosis and other drugs will be conducted by Nitto and the new company. By establishing this new company with a focus on pharmaceutical development, Nitto will be able to further expand its future business options and opportunities for Nitto groups.

Under the slogan of “Innovation for Customers”, Nitto plans to continue expanding their business reach in the Green (Environment) / Clean (New Energy) / Fine (Life Sciences) domains in order to contribute to our customer’s value creation. Taking the opportunity of establishing this new company, Nitto will promote drug discovery for intractable diseases, such as fibrosis, which are activities in Fine (Life Sciences) domain.

New Company Outline
Company Name: Nitto BioPharma, Inc.
President: Kageshi Maruyama (Senior Vice President of Nitto Denko Corporation)
Company Address: 10628 Science Center Drive, San Diego, CA, USA (Planning from June, 2016)
Date of Establishment: January 11, 2016

View source version on businesswire.com: http://www.businesswire.com/news/home/20160125005556/en/

CONTACT

Nitto Denko Corporation
Toshiaki Minagawa / Rie Miura,
+81-6-7632-2101
Brand Strategy Dept., Corporate Strategy Management
Div.
FAX: +81-6-7632-2568
communication_group@nitto.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection
  • EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
  • BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
  • ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
  • Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen